Xenetic Biosciences Inc
Research Xenetic Biosciences Inc (XBIO) on Bullrun: market cap USD 8.95M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.95M
- Financial periodQ2 2026
- RevenueUSD 660.60K
- Net income-USD 929.70K
- Free cash flow-USD 875.49K
Valuation Snapshot
latest market cap is USD 8.95M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.98M | -USD 2.68M | -USD 2.29M | n/a | -1.58 | USD 7.88M | n/a | USD 7.40M |
| FY2024 | USD 2.50M | -USD 3.96M | -USD 2.82M | n/a | -2.57 | USD 6.17M | n/a | USD 6.01M |
| FY2023 | USD 2.54M | -USD 4.13M | n/a | n/a | -2.71 | USD 8.98M | n/a | USD 9.80M |
| FY2022 | USD 1.71M | -USD 6.55M | n/a | n/a | -4.61 | USD 13.10M | n/a | USD 13.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.95M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.97M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.15M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.32M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.32M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 17.34M | n/a | n/a | n/a |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xenetic Biosciences Inc's market cap?
Xenetic Biosciences Inc's market capitalization is USD 8.95M.
What does Xenetic Biosciences Inc do?
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.